Ozempic Is a Hit. So Why Is the Drugmaker’s CEO Out?
Blockbuster drugs. Rising profits. Strong sales. And yet, Novo Nordisk, the Danish company behind the GLP-1 drugs Ozempic and Wegovy, made a surprising move last week: It pushed out its CEO. WSJ’s Peter Loftus charts the rise of Ozempic and the fall of CEO Lars Jorgensen. Jessica Mendoza hosts. Further Listening: Trillion Dollar Shot Why […]
Cigna debuts GLP-1 copay cap
Cigna subsidiary Evernorth Health Services will automate prior authorizations for GLP-1 weight-loss drugs under a new program
The GLP-1 Drug Landscape Changes on Thursday
The GLP-1 drug landscape is about to change. Starting Thursday, off-brand versions of semaglutide will no longer be permitted to be sold—creating a possible problem for the Americans who’ve come to rely on the generally cheaper option. The FDA in February announced that the shortage of the active ingredient…